Menu
Recruiting NCT07221409

Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment

No phase Interventional Adjustment Disorder Anxiety Disorder Depression Hematopoietic and Lymphoid System Neoplasm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Questionnaire Administration, Virtual Reality (VR) Intervention.
Who it may be relevant to
Registry conditions: Adjustment Disorder, Anxiety Disorder, Depression, Hematopoietic and Lymphoid System Neoplasm. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Pilot Study to Assess Safety, Tolerability and Efficacy of Virtual Reality in Cancer Patients

Overview

This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.

Interventions

  • Other Questionnaire Administration
    Participants will complete pre- and post-intervention questionnaires to assess symptoms of anxiety, depression, and fatigue.
  • Other Virtual Reality (VR) Intervention
    Participants will engage in a single-session immersive Virtual Reality (VR) experience lasting approximately 20-30 minutes. The VR content will include calming, guided experiences such as nature scenes, meditation, or breathing exercises designed to promote relaxation and reduce psychological distress. The intervention will be administered in a clinical setting.

Primary outcome measures

  • Successfully complete the virtual reality (VR) intervention (Feasibility) [Time frame: Baseline]
  • Absence of major issues during administration (Feasibility) [Time frame: Baseline]
  • Acceptability [Time frame: Baseline]
Secondary outcome measures (4)
  • Change in anxiety [Time frame: Baseline (pre- to post-intervention, approximately 1.5 hours)]
  • Change in depression [Time frame: Baseline (pre- to post-intervention, approximately 1.5 hours)]
  • Change in fatigue [Time frame: Baseline (pre- to post-intervention, approximately 1.5 hours)]
  • Change in overall quality of life [Time frame: Baseline (pre- to post-intervention, approximately 1.5 hours)]

Eligibility criteria

Inclusion criteria

  • History of cancer
  • Age between 18 to 90 years
  • Undergoing in-patient chemotherapy, bone marrow transplant (BMT), chimeric antigen receptor (CAR)-t, \& out-patient chemotherapy

Exclusion criteria

  • History of bipolar disorder, major depression, bipolar disorder, anxiety disorder, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), psychotic disorder, schizophrenia, personality disorder, substance use disorder other than caffeine or tobacco. History of suicidal ideation or attempt
  • History of treatment resistant depression, psychiatric hospitalization, syncope, transient ischemic attack (TIA), stroke, epilepsy, electroconvulsive therapy, benign positional vertigo, Meniere's disease

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • Mayo Clinic in Florida — Jacksonville

Identifiers

NCT: NCT07221409 · 25-002609 · NCI-2025-07303 · 25-002609

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗